Please login to the form below

Not currently logged in
Email:
Password:

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi has had a challenging few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma

Latest news

More from news
Approximately 22 fully matching, plus 123 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    protection for Lantus (insulin glargine) – as well as cardiovascular disease research.

  • Deal Watch October 2018

    agreement for the development and commercialisation of a follow‐on insulin glargine product to Sanofi’s Lantus.

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    As biosimilars surge into the insulin market, governments  are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi

  • Going the distance Going the distance

    In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the

  • Pharma deals during February 2013 Pharma deals during February 2013

    Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...